BRISTOL-MYERS SQUIBB CO (BRM.DE) Fundamental Analysis & Valuation
FRA:BRM • US1101221083
Current stock price
51.68 EUR
-1.24 (-2.34%)
Last:
This BRM.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BRM.DE Profitability Analysis
1.1 Basic Checks
- BRM had positive earnings in the past year.
- In the past year BRM had a positive cash flow from operations.
- Of the past 5 years BRM 4 years were profitable.
- In the past 5 years BRM always reported a positive cash flow from operatings.
1.2 Ratios
- BRM's Return On Assets of 7.83% is in line compared to the rest of the industry. BRM outperforms 53.85% of its industry peers.
- Looking at the Return On Equity, with a value of 38.19%, BRM belongs to the top of the industry, outperforming 88.46% of the companies in the same industry.
- BRM has a Return On Invested Capital of 19.52%. This is in the better half of the industry: BRM outperforms 75.00% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for BRM is below the industry average of 17.75%.
- The 3 year average ROIC (14.47%) for BRM is below the current ROIC(19.52%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.83% | ||
| ROE | 38.19% | ||
| ROIC | 19.52% |
ROA(3y)2.2%
ROA(5y)3.91%
ROE(3y)3.56%
ROE(5y)10.1%
ROIC(3y)14.47%
ROIC(5y)12.91%
1.3 Margins
- With a Profit Margin value of 14.64%, BRM perfoms like the industry average, outperforming 55.77% of the companies in the same industry.
- In the last couple of years the Profit Margin of BRM has grown nicely.
- BRM has a Operating Margin of 35.82%. This is amongst the best in the industry. BRM outperforms 84.62% of its industry peers.
- BRM's Operating Margin has improved in the last couple of years.
- BRM has a Gross Margin (72.63%) which is in line with its industry peers.
- BRM's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 35.82% | ||
| PM (TTM) | 14.64% | ||
| GM | 72.63% |
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
2. BRM.DE Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BRM is creating value.
- BRM has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for BRM has been reduced compared to 5 years ago.
- Compared to 1 year ago, BRM has an improved debt to assets ratio.
2.2 Solvency
- BRM has an Altman-Z score of 2.53. This is not the best score and indicates that BRM is in the grey zone with still only limited risk for bankruptcy at the moment.
- BRM has a Altman-Z score (2.53) which is in line with its industry peers.
- BRM has a debt to FCF ratio of 3.51. This is a good value and a sign of high solvency as BRM would need 3.51 years to pay back of all of its debts.
- BRM has a Debt to FCF ratio of 3.51. This is in the better half of the industry: BRM outperforms 63.46% of its industry peers.
- BRM has a Debt/Equity ratio of 2.33. This is a high value indicating a heavy dependency on external financing.
- Looking at the Debt to Equity ratio, with a value of 2.33, BRM is doing worse than 78.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.33 | ||
| Debt/FCF | 3.51 | ||
| Altman-Z | 2.53 |
ROIC/WACC2.25
WACC8.69%
2.3 Liquidity
- A Current Ratio of 1.26 indicates that BRM should not have too much problems paying its short term obligations.
- BRM has a Current ratio (1.26) which is in line with its industry peers.
- BRM has a Quick Ratio of 1.14. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
- BRM has a better Quick ratio (1.14) than 63.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.14 |
3. BRM.DE Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 439.47% over the past year.
- BRM shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -0.92% yearly.
- The Revenue has decreased by -0.22% in the past year.
- BRM shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.54% yearly.
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
3.2 Future
- BRM is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.15% yearly.
- BRM is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.54% yearly.
EPS Next Y2.98%
EPS Next 2Y0.29%
EPS Next 3Y-4.05%
EPS Next 5Y-4.15%
Revenue Next Year-1.85%
Revenue Next 2Y-1.95%
Revenue Next 3Y-5.42%
Revenue Next 5Y-5.54%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. BRM.DE Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 9.68 indicates a reasonable valuation of BRM.
- 90.38% of the companies in the same industry are more expensive than BRM, based on the Price/Earnings ratio.
- When comparing the Price/Earnings ratio of BRM to the average of the S&P500 Index (25.60), we can say BRM is valued rather cheaply.
- With a Price/Forward Earnings ratio of 9.40, the valuation of BRM can be described as very reasonable.
- BRM's Price/Forward Earnings ratio is rather cheap when compared to the industry. BRM is cheaper than 94.23% of the companies in the same industry.
- BRM's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.84.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.68 | ||
| Fwd PE | 9.4 |
4.2 Price Multiples
- BRM's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BRM is cheaper than 88.46% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, BRM is valued cheaper than 90.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.44 | ||
| EV/EBITDA | 7.28 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BRM does not grow enough to justify the current Price/Earnings ratio.
- The decent profitability rating of BRM may justify a higher PE ratio.
- A cheap valuation may be justified as BRM's earnings are expected to decrease with -4.05% in the coming years.
PEG (NY)3.25
PEG (5Y)N/A
EPS Next 2Y0.29%
EPS Next 3Y-4.05%
5. BRM.DE Dividend Analysis
5.1 Amount
- BRM has a Yearly Dividend Yield of 4.24%, which is a nice return.
- Compared to an average industry Dividend Yield of 1.95, BRM pays a better dividend. On top of this BRM pays more dividend than 82.69% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.88, BRM pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.24% |
5.2 History
- The dividend of BRM is nicely growing with an annual growth rate of 6.51%!
Dividend Growth(5Y)6.51%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
- BRM pays out 71.52% of its income as dividend. This is not a sustainable payout ratio.
- The Dividend Rate of BRM has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.
DP71.52%
EPS Next 2Y0.29%
EPS Next 3Y-4.05%
BRM.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:BRM (4/2/2026, 7:00:00 PM)
51.68
-1.24 (-2.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05 2026-02-05/bmo
Earnings (Next)04-30 2026-04-30
Inst Owners83.3%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap105.24B
Revenue(TTM)48.19B
Net Income(TTM)7.05B
Analysts70.56
Price Target52.4 (1.39%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.24% |
Yearly Dividend2.18
Dividend Growth(5Y)6.51%
DP71.52%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.39%
Min EPS beat(2)6.92%
Max EPS beat(2)11.85%
EPS beat(4)4
Avg EPS beat(4)18.29%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.75%
EPS beat(12)11
Avg EPS beat(12)12.26%
EPS beat(16)15
Avg EPS beat(16)10.82%
Revenue beat(2)2
Avg Revenue beat(2)1.61%
Min Revenue beat(2)0.79%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)3.42%
Min Revenue beat(4)0.79%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.86%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)12
Avg Revenue beat(16)1.77%
PT rev (1m)0%
PT rev (3m)11.1%
EPS NQ rev (1m)0.88%
EPS NQ rev (3m)0.6%
EPS NY rev (1m)4.07%
EPS NY rev (3m)4.48%
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)2.94%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)6.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.68 | ||
| Fwd PE | 9.4 | ||
| P/S | 2.52 | ||
| P/FCF | 9.44 | ||
| P/OCF | 8.57 | ||
| P/B | 6.57 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.28 |
EPS(TTM)5.34
EY10.33%
EPS(NY)5.5
Fwd EY10.63%
FCF(TTM)5.47
FCFY10.59%
OCF(TTM)6.03
OCFY11.67%
SpS20.53
BVpS7.87
TBVpS-9.54
PEG (NY)3.25
PEG (5Y)N/A
Graham Number30.75
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.83% | ||
| ROE | 38.19% | ||
| ROCE | 25.91% | ||
| ROIC | 19.52% | ||
| ROICexc | 23.22% | ||
| ROICexgc | 84.94% | ||
| OM | 35.82% | ||
| PM (TTM) | 14.64% | ||
| GM | 72.63% | ||
| FCFM | 26.65% |
ROA(3y)2.2%
ROA(5y)3.91%
ROE(3y)3.56%
ROE(5y)10.1%
ROIC(3y)14.47%
ROIC(5y)12.91%
ROICexc(3y)17.24%
ROICexc(5y)15.38%
ROICexgc(3y)72.12%
ROICexgc(5y)85.46%
ROCE(3y)19.19%
ROCE(5y)17.14%
ROICexgc growth 3Y-3.78%
ROICexgc growth 5Y13.73%
ROICexc growth 3Y21.19%
ROICexc growth 5Y33.96%
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
F-Score7
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.33 | ||
| Debt/FCF | 3.51 | ||
| Debt/EBITDA | 2.03 | ||
| Cap/Depr | 32.69% | ||
| Cap/Sales | 2.72% | ||
| Interest Coverage | 8.22 | ||
| Cash Conversion | 66.54% | ||
| Profit Quality | 182.1% | ||
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z | 2.53 |
F-Score7
WACC8.69%
ROIC/WACC2.25
Cap/Depr(3y)19.36%
Cap/Depr(5y)15.61%
Cap/Sales(3y)2.66%
Cap/Sales(5y)2.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
EPS Next Y2.98%
EPS Next 2Y0.29%
EPS Next 3Y-4.05%
EPS Next 5Y-4.15%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
Revenue Next Year-1.85%
Revenue Next 2Y-1.95%
Revenue Next 3Y-5.42%
Revenue Next 5Y-5.54%
EBIT growth 1Y49.54%
EBIT growth 3Y14.87%
EBIT growth 5Y23.65%
EBIT Next Year23.75%
EBIT Next 3Y2.42%
EBIT Next 5Y-1.47%
FCF growth 1Y-7.87%
FCF growth 3Y2.44%
FCF growth 5Y-0.69%
OCF growth 1Y-6.81%
OCF growth 3Y2.71%
OCF growth 5Y0.15%
BRISTOL-MYERS SQUIBB CO / BRM.DE Fundamental Analysis FAQ
What is the fundamental rating for BRM stock?
ChartMill assigns a fundamental rating of 5 / 10 to BRM.DE.
What is the valuation status of BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
ChartMill assigns a valuation rating of 7 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.
Can you provide the profitability details for BRISTOL-MYERS SQUIBB CO?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for BRM stock?
The Price/Earnings (PE) ratio for BRISTOL-MYERS SQUIBB CO (BRM.DE) is 9.68 and the Price/Book (PB) ratio is 6.57.
Can you provide the financial health for BRM stock?
The financial health rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 5 / 10.